Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease andMortality

RESULTS Forty-two trials, including 144 220 patients, met the eligibility criteria. In general, there were linear associations between mean achieved SBP and risk of cardiovascular disease and mortality, with the lowest risk at 120 to 124 mm Hg. Randomized groups with a mean achieved SBP of 120 to 124 mm Hg had a hazard ratio (HR) for major cardiovascular disease of 0.71 (95% CI, 0.60-0.83) compared with randomized groups with a mean achieved SBP of 130 to 134 mm Hg, an HR of 0.58 (95% CI, 0.48-0.72) compared with those with a mean achieved SBP of 140 to 144 mm Hg, an HR of 0.46 (95% CI, 0.34-0.63) compared with those with a mean achieved SBP of 150 to 154 mm Hg, and an HR of 0.36 (95% CI, 0.26-0.51) compared with those with a mean achieved SBP of 160 mm Hg or more. Likewise, randomized groups with a mean achieved SBP of 120 to 124 mm Hg had an HR for all-cause mortality of 0.73 (95% CI, 0.58-0.93) compared with randomized groups with a mean achieved SBP of 130 to 134 mm Hg, an HR of 0.59 (95% CI, 0.45-0.77) compared with those with a mean achieved SBP of 140 to 144 mm Hg, an HR of 0.51 (95% CI, 0.36-0.71) compared with those with a mean achieved SBP of 150 to 154 mm Hg, and an HR of 0.47 (95% CI, 0.32-0.67) compared with those with a mean achieved SBP of 160 mm Hg or more.

[1]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[2]  Bo Carlberg,et al.  Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .

[3]  Daniel W. Jones,et al.  SPRINT: What Remains Unanswered and Where Do We Go From Here? , 2016, Hypertension.

[4]  M. Woodward,et al.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.

[5]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[6]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[7]  Dan Jackson,et al.  A design-by-treatment interaction model for network meta-analysis with random inconsistency effects , 2014, Statistics in medicine.

[8]  J. Cutler,et al.  Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial , 2014, Diabetes Care.

[9]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[10]  G. Mancia,et al.  Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. , 2014, Hypertension.

[11]  A. Schutte,et al.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.

[12]  Sofia Dias,et al.  Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta‐analysis to network meta‐analysis , 2013, Statistics in medicine.

[13]  Lawrence A Leiter,et al.  Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. , 2012, Archives of internal medicine.

[14]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[15]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[16]  S Dias,et al.  Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.

[17]  G. Panjrath,et al.  The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? , 2009, Journal of the American College of Cardiology.

[18]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[19]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[20]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[21]  F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[22]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[23]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[24]  Bo Carlberg,et al.  Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses , 2016 .

[25]  Daniel W. Jones,et al.  SPRINT: What Remains Unanswered and Where Do We Go From Here? , 2016, Hypertension.

[26]  M. Woodward,et al.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.

[27]  A. Rodgers,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[28]  Dan Jackson,et al.  A design-by-treatment interaction model for network meta-analysis with random inconsistency effects , 2014, Statistics in medicine.

[29]  J. Cutler,et al.  Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial , 2014, Diabetes Care.

[30]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[31]  G. Mancia,et al.  Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. , 2014, Hypertension.

[32]  A. Schutte,et al.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.

[33]  Jiguang Wang,et al.  Effects of Intensive Antihypertensive Treatment on Chinese Hypertensive Patients Older Than 70 Years , 2013, Journal of clinical hypertension.

[34]  Julian P T Higgins,et al.  Evaluation of inconsistency in networks of interventions. , 2013, International journal of epidemiology.

[35]  Sofia Dias,et al.  Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta‐analysis to network meta‐analysis , 2013, Statistics in medicine.

[36]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials. , 2013 .

[37]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[38]  Lawrence A Leiter,et al.  Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. , 2012, Archives of internal medicine.

[39]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[40]  C. Bias The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .

[41]  W. Elliott Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly: Valsartan in Elderly Isolated Systolic Hypertension Study , 2011 .

[42]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[43]  S Dias,et al.  Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.

[44]  W. Elliott The J-Curve Between Blood Pressure and Coronary Artery Disease or Essential Hypertension: Exactly How Essential? , 2010 .

[45]  Li-sheng Liu,et al.  Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature , 2009, Hypertension Research.

[46]  石井當男 Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS) , 2008, Hypertension Research.

[47]  W. Zidek,et al.  Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[49]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[50]  Keith C. Norris,et al.  Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  G. Lu,et al.  Assessing Evidence Inconsistency in Mixed Treatment Comparisons , 2006 .

[52]  W. Elliott Global Burden of Hypertension: Analysis of Worldwide Data , 2006 .

[53]  J. Staessen,et al.  Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003–2004 Secondary Prevention Trials , 2005, Hypertension Research.

[54]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[55]  P. Libby,et al.  Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled Trial , 2004 .

[56]  Hans L. Hillege,et al.  Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria , 2004, Circulation.

[57]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[58]  P. Poole‐Wilson,et al.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial , 2004, The Lancet.

[59]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[60]  F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[61]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[62]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[63]  W. Desmet,et al.  Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study , 2003, Heart.

[64]  S. Lewington Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[65]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[66]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[67]  P. Mehler,et al.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.

[68]  Sc Prospective,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .

[69]  Michael E. Miller,et al.  Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.

[70]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[71]  Andrew Gelman,et al.  General methods for monitoring convergence of iterative simulations , 1998 .

[72]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[73]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[74]  W. Shen,et al.  Beneficial effects of captopril on prognosis in patients with acute myocardial infarction. Shanghai Secondary Prevention of Acute Myocardial Infarction Study Group. , 1996, Chinese medical journal.

[75]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[76]  L. Passman,et al.  The treatment of mild hypertension study. , 1993, JAMA.

[77]  M. Mondal,et al.  Effect of vasodilator therapy on mortality in chronic congestive heart failure. , 1993, The Journal of the Association of Physicians of India.

[78]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[79]  C. Bulpitt,et al.  Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial , 1985, The Lancet.

[80]  A. Helgeland Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. , 1980, The American journal of medicine.

[81]  J. Abernethy The Australian National Blood Pressure Study: a test of the effectiveness of antihypertensive therapy on the incidence of ischaemic heart disease. , 1976, Australian and New Zealand journal of medicine.

[82]  Lull Gf,et al.  THE AMERICAN MEDICAL ASSOCIATION. , 1947, Science.